Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL 8: Somapacitan vs Norditropin in Children With Short Stature
NCT05330325Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 33
01
Overview
Phase 3, randomised trial of somapacitan in short stature, Small for gestational age (SGA), Turner syndrome (TS) and 2 more (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity at 52 weeks. Started Aug 2022; status: active, not recruiting.
02
Drugs
somapacitan
03
Conditions
short statureSmall for gestational age (SGA)Turner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT05330325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330325.